Further work in xenograft models confirms not only the enhanced sensitivity of MLL-r leukemias to BCL-2 inhibition compared to other subgroups of ALL but also the enhanced efficacy of combined inhibition of BCL-2 and BCL-XL (230). This evidence concerns the gene KMT2A and acute lymphoblastic leukemia.